Abstract 4123
Background
“The South Thailand Insurgency” is burning violence in the deep south of Thailand. The insurgency which has been ongoing since 2004 has played out in the three southern most districts of the country Pattani, Yala and Narathiwat and some area of Songkhla, so-called the “Red Zone”. Violence such as daily ambush, bombing on soldiers and civilians, caused people living in terror. This violence has affected cancer service. Many cancer patients gave up on their lives due to struggle with the disease itself, security concerns, traveling and caregiving burden led to a high loss to follow-up rate. We, an oncology service team working at Songklanagarind hospital, the only one radiation and oncology center located in this area, in cooperation with doctors and nurses working in the Red Zone created a network and utilized an electronic consultation and referral system to alleviate these suffering. We preliminarily reported its real-life performance in 3 years period.
Methods
Electronic consultation system(E-consult) was a web-based program designed and developed to provide advice and facilitate the referral process in cancer care. Since October 2015, we prospectively surveyed the impact of this pilot project on the quality of service by counting waiting time, the number of center visit until treatment, unnecessary referral avoidance, patient and potential cost saving compared to the normal referral system.
Results
E-consult reached out to 7 hospitals and 589 patient referred through E-consult. Among patients from the Red Zone, without E-consult, their average waiting time was 56.4 days, the number of visits was 6.5 visits. The estimated financial burden was $758.8 per patient. After the implementation of E-consult in 259 patients, the average time to treatment was 41.5 days (p = 0.006) and the number of counter visit was 2.3 visits (p < 0.001). The estimated financial burden was $358.7(p < 0.001). We prevented 28 patients from the unnecessary referral.
Conclusions
In this special context, the electronic referral system not only was helpful to improve medical access, timeliness to specialist care, saving the patients’ family time and resources but it also supports the doctors and nurses on duty in the Red Zone.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nanthiya Rattanakhot.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract